Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.780
+0.150 (3.24%)
Dec 20, 2024, 4:00 PM EST - Market closed
Vanda Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 190.86 | 192.64 | 254.38 | 268.68 | 248.17 | 227.19 | Upgrade
|
| Revenue Growth (YoY) | -9.91% | -24.27% | -5.32% | 8.27% | 9.23% | 17.64% | Upgrade
|
| Cost of Revenue | 12.18 | 14.8 | 24.28 | 25.63 | 23.36 | 24.49 | Upgrade
|
| Gross Profit | 178.67 | 177.84 | 230.1 | 243.05 | 224.8 | 202.7 | Upgrade
|
| Selling, General & Admin | 130.75 | 112.88 | 136.49 | 124.05 | 140.51 | 129.74 | Upgrade
|
| Research & Development | 78.93 | 76.82 | 85.77 | 75.36 | 55.58 | 48.65 | Upgrade
|
| Operating Expenses | 216.15 | 191.8 | 223.77 | 200.89 | 197.57 | 179.89 | Upgrade
|
| Operating Income | -37.48 | -13.95 | 6.33 | 42.17 | 27.24 | 22.81 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 4.42 | 6.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 11.49 | 11.49 | 2.01 | 1.85 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -26.88 | -2.46 | 8.34 | 44.01 | 31.66 | 29.03 | Upgrade
|
| Gain (Loss) on Sale of Investments | 8.8 | 8.8 | 2.96 | -1.65 | - | - | Upgrade
|
| Pretax Income | -18.09 | 6.34 | 11.3 | 42.36 | 31.66 | 29.03 | Upgrade
|
| Income Tax Expense | -1.7 | 3.83 | 5.03 | 9.21 | 8.32 | -86.53 | Upgrade
|
| Net Income | -16.39 | 2.51 | 6.28 | 33.15 | 23.34 | 115.55 | Upgrade
|
| Net Income to Common | -16.39 | 2.51 | 6.28 | 33.15 | 23.34 | 115.55 | Upgrade
|
| Net Income Growth | - | -60.02% | -81.07% | 42.06% | -79.80% | 358.40% | Upgrade
|
| Shares Outstanding (Basic) | 58 | 57 | 56 | 56 | 54 | 53 | Upgrade
|
| Shares Outstanding (Diluted) | 58 | 58 | 57 | 57 | 55 | 55 | Upgrade
|
| Shares Change (YoY) | 0.24% | 1.01% | 0.11% | 3.14% | 0.63% | 3.40% | Upgrade
|
| EPS (Basic) | -0.28 | 0.04 | 0.11 | 0.60 | 0.43 | 2.17 | Upgrade
|
| EPS (Diluted) | -0.29 | 0.04 | 0.11 | 0.58 | 0.42 | 2.11 | Upgrade
|
| EPS Growth | - | -63.64% | -81.03% | 38.10% | -80.09% | 339.58% | Upgrade
|
| Free Cash Flow | -123.1 | -88.25 | 31.31 | 63.66 | 49.98 | 44.93 | Upgrade
|
| Free Cash Flow Per Share | -2.12 | -1.53 | 0.55 | 1.12 | 0.91 | 0.82 | Upgrade
|
| Gross Margin | 93.62% | 92.32% | 90.45% | 90.46% | 90.59% | 89.22% | Upgrade
|
| Operating Margin | -19.64% | -7.24% | 2.49% | 15.69% | 10.98% | 10.04% | Upgrade
|
| Profit Margin | -8.59% | 1.30% | 2.47% | 12.34% | 9.40% | 50.86% | Upgrade
|
| Free Cash Flow Margin | -64.50% | -45.81% | 12.31% | 23.69% | 20.14% | 19.78% | Upgrade
|
| EBITDA | -30.16 | -10.94 | 9.06 | 45.01 | 30.1 | 25.7 | Upgrade
|
| EBITDA Margin | -15.80% | -5.68% | 3.56% | 16.75% | 12.13% | 11.31% | Upgrade
|
| D&A For EBITDA | 7.32 | 3.01 | 2.73 | 2.84 | 2.86 | 2.89 | Upgrade
|
| EBIT | -37.48 | -13.95 | 6.33 | 42.17 | 27.24 | 22.81 | Upgrade
|
| EBIT Margin | -19.64% | -7.24% | 2.49% | 15.69% | 10.98% | 10.04% | Upgrade
|
| Effective Tax Rate | - | 60.42% | 44.47% | 21.74% | 26.28% | - | Upgrade
|
| Revenue as Reported | 190.86 | 192.64 | 254.38 | 268.68 | 248.17 | 227.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.